A prospective study of infliximab withdrawal after 12 months of treatment in patients with Crohn's disease: how will NICE guidance affect patient care?

Author： Blackmore Laura   Harris Adam  

Publisher： Royal College Of Physicians

ISSN： 1470-2118

Source： Clinical Medicine, Vol.12, Iss.3, 2012-06, pp. : 235-238

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

UK NICE issues guidance on infliximab in Crohn's disease

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 363, 2002-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

UK NICE issues guidance on infliximab in Crohn's disease

By  

Inpharma, Vol. 1, Iss. 1338, 2002-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Managing Immunogenic Responses to Infliximab: Treatment Implications for Patients with Crohn’s Disease

By Peter D. Han   Russell D. Cohen  

Drugs, Vol. 64, Iss. 16, 2004-01 ,pp. : 1767-1777

Adis International

Access to resources Recommend Favorite

Toxicity of infliximab in the course of treatment of Crohn’s disease

By Bratcher Jason M   Korelitz Burton I  

Expert Opinion on Drug Safety, Vol. 5, Iss. 1, 2006-01 ,pp. : 9-16

Informa Healthcare

Access to resources Recommend Favorite

Infliximab: First reports of colorectal cancer in patients with Crohn's disease (one in an elderly patient and one fatal): 2 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1075, 2005-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite